Selection of clinical, patient-reported, and economic end points in acute exacerbation of chronic bronchitis

Perfetto, Elèanor M.; Mullins, C. Daniel; Subedi, Prasun; Li-McLeod, Josephine

doi:10.1016/s0149-2918(01)80142-9

Cited by 6 publications

(2 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Perfetto et al (20) recommended that patient-reported outcomes of work loss and productivity level at work be included as endpoints in studies of AECB. However, most of the studies reviewed in this manuscript, as well as most studies evaluating diseaserelated workplace absenteeism in general, rely on selfreported data for days of work missed.…”

Section: Discussionmentioning

confidence: 99%

The Workplace Impact of Acute Exacerbations of Chronic Bronchitis (AECB); A Literature Review

Halpern

Polzin

Higashi

et al. 2004

COPD: Journal of Chronic Obstructive Pulmonary Disease

View full text Add to dashboard Cite

Acute exacerbations of chronic bronchitis (AECB) are known to have a substantial economic burden in terms of medical care costs. The objective of this study was to assess workplace-based costs associated with AECB, including absenteeism and decreased productivity, based on a review of published literature. A secondary goal was to identify factors related to workplace-based costs in AECB. A literature search was conducted to identify relevant articles assessing one or more aspects of work loss or workplace costs among patients with chronic bronchitis. A review of the identified literature indicates that patients with chronic bronchitis had more days off work; patients whose exacerbations were treated were less likely to have additional exacerbations and had comparatively less work loss. Findings suggest that clinical outcomes and workplace costs are related. While this relationship is clearer in terms of work loss, further exploration is needed to assess decreased productivity and to evaluate this relationship using objective indicators of absenteeism and productivity rather than recall.

show abstract

Section: Discussionmentioning

confidence: 99%

The Workplace Impact of Acute Exacerbations of Chronic Bronchitis (AECB); A Literature Review

Halpern

Polzin

Higashi

et al. 2004

COPD: Journal of Chronic Obstructive Pulmonary Disease

View full text Add to dashboard Cite

show abstract

“…There have been few studies addressing this issue, the results of which are applicable on a large-scale. (24) In a retrospective study, the use of third-generation antibiotics (azithromycin, ciprofloxacin and amoxicillin/clavulanic acid) in comparison to that of first-generation antibiotics (amoxicillin, sulfamethoxazole/trimethoprim, erythromycin and tetracycline) was found to be associated with lower rates of treatment failure/ hospitalization, longer intervals between exacerbation episodes and (a tendency toward) lower overall treatment costs. (25) The results of the present study confirm the efficacy and tolerability of azithromycin for the outpatient treatment of episodes of infectious exacerbation of COPD.…”

Section: Discussionmentioning

confidence: 99%

Comparação entre a azitromicina e a amoxicilina no tratamento da exacerbação infecciosa da doença pulmonar obstrutiva crônica

et al. 2007

View full text Add to dashboard Cite

Objective: To compare the efficacy, safety, and tolerability of azithromycin and amoxicillin in the treatment of patients with infectious exacerbation of chronic obstructive pulmonary disease. Methods: This study was conducted at six medical centers across Brazil and included 109 patients from 33 to 82 years of age. Of those, 102 were randomized to receive either azithromycin (500 mg/day for three days, n = 49) or amoxicillin (500 mg every eight hours for ten days, n = 53). The patients were evaluated at the study outset, on day ten, and at one month. Based on the clinical evaluation of the signs and symptoms present on day ten and at one month, the outcomes were classified as cure, improvement, or treatment failure. The microbiological evaluation was made through the culture of sputum samples that were considered appropriate samples only after leukocyte counts and Gram staining. Secondary efficacy evaluations were made in order to analyze symptoms (cough, dyspnea, and expectoration) and pulmonary function. Results: There were no differences between the groups treated with azithromycin or amoxicillin in terms of the percentages of cases in which the outcomes were classified as cure or improvement: 85% vs. 78% (p = 0.368) on day ten; and 83% vs. 78% (p = 0.571) at one month. Similarly, there were no significant differences between the two groups in the secondary efficacy variables or the incidence of adverse effects. Conclusion: Azithromycin and amoxicillin present similar efficacy and tolerability in the treatment of acute exacerbation of chronic obstructive pulmonary disease.

show abstract

Acute Exacerbations of Chronic Bronchitis

2006

Wiley Handbook of Current and Emerging Drug Therapies

View full text Add to dashboard Cite

show abstract

Selection of clinical, patient-reported, and economic end points in acute exacerbation of chronic bronchitis

Cited by 6 publications

References 76 publications

The Workplace Impact of Acute Exacerbations of Chronic Bronchitis (AECB); A Literature Review

The Workplace Impact of Acute Exacerbations of Chronic Bronchitis (AECB); A Literature Review

Comparação entre a azitromicina e a amoxicilina no tratamento da exacerbação infecciosa da doença pulmonar obstrutiva crônica

Acute Exacerbations of Chronic Bronchitis

Contact Info

Product

Resources

About